Eikon Therapeutics, Inc. (EIKN)
EIKNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$5.98
-0.0600 (-0.99%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $324.03m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.01 to $17.40
- Average volume
- –
- Previous close
- $6.04
Earnings
next estimate $-1.88Next report
Mar 2026
-67.3%
Jun 2026
-1.2%
Sep 2026
+8.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$83.17m | -$87.34m | -$93.39m | -$90.55m |
| Net income | -$79.66m | -$82.96m | -$88.41m | -$86.11m |
News
8 latest- Eikon Therapeutics, Inc. Loss At -$86.112 Mln In Q3 RTTNews · 3 days ago
- Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029MarketBeat · Nov 6, 2026
- HC Wainwright & Co. Initiates Coverage of Eikon Therapeutics with Buy RatingFintel · Oct 16, 2026
- Eikon Submits IND For EIK1006 In Prostate Cancer; Stock Up Over 8% RTTNews · Oct 15, 2026
- Eikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific Officer RTTNews · Sep 3, 2026
- Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004MarketBeat · Aug 22, 2026
- Eikon Therapeutics Selects 0.60 Mg/m² Dose For Phase 2/3 EIK1001 Melanoma Trial RTTNews · Aug 11, 2026
- Eikon Doses First Patient In Phase 2/3 TeLuRide For EIK1001 For NSCLC; Stock Up RTTNews · Jul 27, 2026
The company
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- eikontx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.